ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2688 • ACR Convergence 2024

    HLA-DRB4: A Novel Susceptibility Locus in Systemic Sclerosis Patients with Severe Calcinosis

    Sara Faghihi-Kashani1, srijana davluri2, Kamini Kuchinad3, Zuoming deng4, Faiza Naz4, Stefania Dell'Orso4, Zsuzsanna McMahan5, Laura Hummers6, Daniel Kastner7, Fredrick Wigley3, david fiorentino8, Christian Lood9, Ami Shah10, Lorinda Chung11 and Pravitt Gourh4, 1Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, San Francisco, CA, 2Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, Sunnyvale, CA, 3Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, 4National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, 5UTHealth Houston Division of Rheumatology, Houston, TX, 6Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, 7National Human Genome Research Institute, Bethesda, MD, Bethesda, MD, 8Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA, 9Division of Rheumatology, University of Washington, Seattle, WA, Seattle, WA, 10Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, 11Stanford University, Woodside, CA

    Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune disease. Class II HLA alleles have been reported to play an important role in SSc pathogenesis. Calcinosis, deposition of…
  • Abstract Number: 2625 • ACR Convergence 2024

    Brain Injury Markers Correlate with Impaired Executive Function and Disease Activity in Children with Systemic Lupus Erythematosus

    Oscar Mwizerwa1, Justine Ledochowski2, Tala El Tal3, Ganesh Ramanathan2, Sarah Mossad4, Ibrahim Mohamed5, Joanna Law6, Lawrence Ng2, Paris Moaf2, Asha Jeyanathan1, Adrienne Davis7, Ann Yeh2, Linda Hiraki2, Deborah Levy2, Zahi Touma8, Joan Wither9, Busi Zapparoli10, Ashley Danguecan11 and Andrea Knight12, 1The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, 2The Hospital for Sick Children, Toronto, ON, Canada, 3The Hospital For Sick Children & Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 4Hospital for Sick Children, Toronto, ON, Canada, 5The Hospital for Sick Children, Brampton, ON, Canada, 6The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 7Division of Pediatric Emergency Medicine, Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 8University of Toronto, Toronto, ON, Canada, 9University Health Network, Toronto, ON, Canada, 10The Hospital for Sick Children, Etobicoke, ON, Canada, 11The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, 12Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) commonly experience impaired executive function (EF), and attribution to neuropsychiatric lupus (NPSLE) is challenging. Serum markers of…
  • Abstract Number: 2514 • ACR Convergence 2024

    The Pattern of Renal Involvement in Relapsing Cryoglobulinemic Vasculitis After Successful Sustained Viral Response by Direct-Acting Antiviral Treatments

    Mohamed Tharwat Hegazy1, Ahmed Fayed1 and Gaafar Ragab2, 1Faculty of Medicine, Cairo University, Cairo, Egypt, 2Cairo University, Egypt, Cairo, Egypt

    Background/Purpose: Interferon-free Direct Acting Antiviral (DAA) treatments proved to be effective for the treatment of HCV-induced Cryoglobulinemic Vasculitis (HCV-Cryovas). Some reports showed relapses of HCV-Cryovas…
  • Abstract Number: 2681 • ACR Convergence 2024

    Association of Social Determinants of Health with Systemic Lupus Erythematosus in the United States: Nationally Representative Estimates for 2017-2021

    Ami Vyas, Steven Cohen and Christine Eisenhower, University of Rhode Island, Kingston, RI

    Background/Purpose: Careful assessment of individuals’ social determinants of health (SDOH) that affect systemic lupus erythematosus (SLE) is crucial, as such evidence will improve care and…
  • Abstract Number: PP07 • ACR Convergence 2024

    My Journey with Diffuse Scleroderma and Interstitial Lung Disease: A Pharmacist’s Perspective

    Joseph Washington, Cencora, Washington, DC

    Background/Purpose: Since my diagnosis with diffuse scleroderma and ILD, I have balanced the roles of patient and young pharmacist. A duality that has surely impacted…
  • Abstract Number: PP04 • ACR Convergence 2024

    Involving Pediatric Patients in Their Own Care

    Whitney LaBar, Lupus and Allied Diseases Association, Pleasanton, CA

    Background/Purpose: When I was 14, I was diagnosed with thrombocytopenia, which led to more testing and a diagnosis of systemic lupus erythematosus (SLE). As a…
  • Abstract Number: 2510 • ACR Convergence 2024

    The Effect of Coronary Artery Aneurysms and IVIG Use on Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review and Meta-analysis

    Francis Lao1, Cal Robinson2, Dorota Borovski3, KAREN BEATTIE4, Joycelyne Ewusie5, Rahul Chanchlani3 and Michelle Batthish6, 1The Hospital for Sick Children, Hamilton, ON, Canada, 2The Hospital for Sick Children, Toronto, ON, Canada, 3McMaster University, Hamilton, Canada, 4McMaster University, Hamilton, ON, Canada, 5McMaster University, Hamilton, 6McMaster Children's Hospital, Hamilton, ON, Canada

    Background/Purpose: Kawasaki Disease (KD) is a common childhood vasculitis. Coronary artery aneurysms (CAAs) develop in approximately 25% of untreated KD patients. However, there is limited…
  • Abstract Number: PP14 • ACR Convergence 2024

    Support Groups and Chronic Illness: Finding Social Support Among Peers

    Alexandra Blumhorst1 and Estela Mata-Carcamo2, 1Looms for Lupus, Silver Spring, MD, 2Looms for Lupus, Irwindale, CA

    Background/Purpose: Like many lupus patients, my journey has been long, complex, and difficult. I began experiencing symptoms in 2019. Over the next five years, I…
  • Abstract Number: 2646 • ACR Convergence 2024

    Rare Variants in the IL1RAP Gene Implicate the IL-1 Signaling Pathway in the Pathogenesis of Systemic Sclerosis in African and European Ancestries

    Yosuke Kunishita1, Urvashi Kaundal2, Martin Kerick3, Ryan Routsong4, Justin Lack4, Ami Shah5, Maureen Mayes6, Daniel Shriner7, Ayo P. Doumatey7, Amy Bentley7, Robyn Domsic8, Thomas Medsger, Jr9, Paula Ramos10, Richard Silver11, Virginia Steen12, John Varga13, Vivien Hsu14, Lesley Ann Saketkoo15, Dinesh Khanna13, Elena Schiopu16, Jessica Gordon17, Lindsey Criswell18, Heather Gladue19, Chris Derk20, Elana Bernstein21, S. Louis Bridges17, Victoria Shanmugam22, Lorinda Chung23, Suzanne Kafaja24, Reem Jan25, Marcin Trojanowski26, Avram Goldberg27, Benjamin Korman28, James W. Thomas29, Elaine Remmers30, Adebowale Adeyemo7, Charles Rotimi7, Fredrick Wigley31, Francesco Boin32, Javier Martin3, Daniel Kastner33 and Pravitt Gourh34, 1Scleroderma Genomics and Health Disparities Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Scleroderma Genomics and Health Disparities Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Chevy Chase, MD, 3Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Spain, Granada, Spain, 4Integrated Data Sciences Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 5Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, 6UTHealth Houston Division of Rheumatology, Houston, TX, 7Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 8Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 9Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Verona, PA, 10Medical University of South Carolina, Charleston, SC, 11Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, 12Georgetown University School of Medicine, Washington, DC, 13University of Michigan, Ann Arbor, MI, 14Department of Medicine, Rheumatology Division, Rutgers-RWJ Medical School, South Plainfield, NJ, 15New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University and Tulane University Medical Schools, New Orleans, LA, 16Division of Rheumatology, Medical College of Georgia at Augusta University, Martinez, GA, 17Division of Rheumatology, Weill Cornell Medical College, New York, NY, 18Genomics of Autoimmune Rheumatic Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, Bethesda, MD, 19Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, 20Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 21Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, 22Office of Autoimmune Disease Research, Office of Research on Women's Health, National Institutes of Health, Great Falls, VA, 23Stanford University, Woodside, CA, 24Division of Rheumatology, University of California, Los Angeles, Los Angeles, CA, 25Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL, 26Department of Rheumatology, Boston University School of Medicine, Boston, MA, 27NYU Langone Health - NYU Hospital for Joint Diseases, Lake Success, NY, 28University of Rochester, Rochester, NY, 29NIH Intramural Sequencing Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 30Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 31Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, 32Cedars-Sinai Medical Center, Los Angeles, CA, 33National Human Genome Research Institute, Bethesda, MD, 34National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by systemic inflammation and fibrosis. Interleukin-1 receptor accessory protein (IL1RAP) is a co-receptor for the Interleukin-1…
  • Abstract Number: 2662 • ACR Convergence 2024

    In Vivo Generation of B Cell Depleting CAR T Cell Therapies for Treatment of Autoimmune Diseases

    Laurie Beitz1, Maura Parker1, Justin Ulrich-Lewis1, Kristen Mittelsteadt1, Rebecca Gottschalk1, Chris Nicolai1, Jim Qin1, Andrew Scharenberg1, Ryan Larson1, Byoung Ryu1, Eric Cavanaugh2, Weiliang Tang1, Seungjin Shin1, Kelsey Lynch1 and Hans-Peter Kiem2, 1Umoja Biopharma, Seattle, WA, 2Fred Hutch Cancer Research Center, Seattle, WA

    Background/Purpose: CAR T cell therapy promises to revolutionize the treatment of hematologic malignancies, and more recently has generated early data that it may afford long…
  • Abstract Number: 2485 • ACR Convergence 2024

    Orbital Pseudotumor in Granulomatosis with Polyangiitis. Interim Analysis of Clinical Outcomes from a European Collaborative Observational Study

    Luca Moroni1, Gabriele Gallina2, Marco Lanzillotta2, Sara Maggioni2, Giovanni Benanti2, Adriana Cariddi2, Paolo Delvino3, Sara Monti4, Alessandra Milanesi5, Filippo Fagni6, Marco Fornaro7, Camille Taille8, Elena Treppo9, Grégory Pugnet10, Emanuele Chiara11, Roberto Padoan12, Luca Iorio13, Federica Davanzo12, Eleonora Fiorin14, Alvise Berti15, Roberto Bortolotti16, Sergey Moiseev17, Pavel Novikov17, Askin Ates18, Ahmet Omma19, Tahir Saygin Ogut20, Gozde Sevgi Kart-Bayram21, Tuba Demirci22, Riza Can Kardas23, Ömer Karadağ21, Marco Matucci-Cerinic24 and Lorenzo Dagna25, 1IRCCS San Raffaele Scientific Institute, Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), Milano, Italy, Milano, Italy, 2IRCCS Ospedale San Raffaele, Milano, Italy, 3University of Milano-Bicocca, Milan, Milan, Italy, 4IRCCS Istituto Auxologico Italiano, Milan, Italy, 5Unit of Rheumatology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy, 6Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 7Università di Bari, Bari, Italy, 8Bichat Hospital, Paris, France, 9Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, Udine, Italy, 10Toulouse Rangueil University Hospital, Toulouse, France, 11Ospedale Careggi, Firenze, Italy, 12Azienda Ospedaliera-Universitaria di Padova, Padova, Italy, 13Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, Padova, Italy, 14Azienda Ospedaliera-Universitaria di Padova, Padova, 15Rheumatology Unit Santa Chiara Hospital of Trento, Trento, Italy, 16Rheumatology Unit Santa Chiara Hospital of Trento, Trento, 17Sechenov First Moscow State Medical University, Moscow, Russia, 18Ankara University, Ankara, Turkey, 19Ankara Bilkent City Hospital, Ankara, Turkey, 20Akdeniz University, Antalya, Turkey, 21Hacettepe University School of Medicine, Ankara, Turkey, 22Dokuz Eylül University, Izmir, Turkey, 23Gazi University, Ankara, Turkey, 24University San Raffaele Milano, Milano, Milan, Italy, 25Ospedale San Raffaele, Milano, Italy

    Background/Purpose: Orbital Pseudotumor (OPT) is a rare organ-threatening manifestation of Granulomatosis with Polyangiitis (GPA), with severe prognosis and historically refractory to most treatments. This is…
  • Abstract Number: 2482 • ACR Convergence 2024

    Long-Term Safety of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA): Pooled Results from Two Open-Label Extension Studies

    Gerhard Wolff1, Michael E Wechsler2, Jared Silver3, Robert Price4, Rejina Verghis5, Peter Weller6, Peter Merkel7, Thomas Corbridge8 and Paneez Khoury9, 1Clinical Development-Respiratory, GSK, Collegeville, 2Department of Medicine, National Jewish Health, Denver, CO, 3US Medical Affairs-Respiratory, GSK, Durham, 4Biostatistics, GSK, Stevenage, United Kingdom, 5Biostatistics, Development Respiratory, GSK, Brentford, United Kingdom, 6Beth Israel Deaconess Medical Center, Department of Medicine, Division of Allergy and Inflammation, Harvard Medical School, Boston, MA, 7Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, 8US Value Evidence and Outcomes, GSK, Durham, NC, 9National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD

    Background/Purpose: The 52-week Phase III MIRRA trial demonstrated the safety and efficacy of anti-IL-5 mepolizumab in patients with EGPA. However, longer-term safety data are limited.…
  • Abstract Number: 2478 • ACR Convergence 2024

    Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial

    Christian Pagnoux1, Antoine Neel2, Sarah Bray3, Rachel E. Gurlin4, Darcy Trimpe5, David Jayne6 and Peter Merkel7, and ADVOCATE Study Group, 1Mount Sinai Hospital, Toronto, ON, Canada, 2Department of Internal Medicine, CHU Nantes, Nantes, France, 3Amgen Ltd, Cambridge, United Kingdom, 4Amgen Inc., Mountain View, CA, 5Amgen Inc., Thousand Oaks, CA, 6University of Cambridge, Cambridge, United Kingdom, 7University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are subtypes of ANCA-associated vasculitis that frequently involve the kidneys. However, a subset of patients with…
  • Abstract Number: 2505 • ACR Convergence 2024

    C5 Signaling Pathway Genes as Key Drivers of the Pathogenesis of IgA Vasculitis?

    Joao Carlos Batista-Liz1, Vanesa Calvo-Rio2, María Sebastián Mora-Gil3, Ligia Gabrie-Rodriguez4, Rafael Gálvez Sánchez4, Belén Sevilla-Pérez5, José Luis Callejas6, María Teresa Leonardo7, Ana Peñalba7, Javier Narvaez-García8, Luis Martín-Penagos9, Luis Caminal-Montero10, PAZ COLLADO11, Patricia Quiroga Colina12, Esther Vicente-rabaneda13, Esteban Rubio14, Manuel León Luque15, Juan María Blanco-Madrigal16, Eva Galindez-Agirregoikoa17, Santos Castañeda13, Ricardo Blanco-Alonso18, Veronica Pulito-Cueto1 and Raquel Lopez-mejias1, 1IDIVAL, Santander, Spain, 2Valdecilla Hospital, Santander, Cantabria, Spain, 3Immunopathology Group, IDIVAL, Santander, Spain, 4Immunopathology Group, IDIVAL. Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 5Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, 6Systemic Autoimmune Diseases Unit, Hospital Clinico San Cecilio, Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain, 7Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 8Hospital Universitario de Bellvitge, Barcelona, Spain, 9Immunopathology Group, IDIVAL. Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 10Internal Medicine Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain, 11Hospital Universitario Severo Ochoa, MADRID, Spain, 12Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, 13Hospital Universitario de La Princesa, Madrid, Spain, 14Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, Sevilla, Spain, 15Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain., Sevilla, Spain, 16Division of Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain., Bilbao, Spain, 17BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, 18Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Immunoglobulin A Vasculitis (IgAV) is an inflammatory disease caused by the accumulation of immune complexes of IgA in the walls of small blood vessels…
  • Abstract Number: 2512 • ACR Convergence 2024

    French Multicenter Retrospective Study of Patients with Cocaine- and/or Levamisole-induced Vasculitis and Vasculopathy

    Kevin Chevalier1, François Chasset2, Yoann Zerbib3, Pierre-André Jarrot4, Romain Muller4, Thomas Pires5, Saroumadi Adavane6, Didier Bessis7, Alban Deroux8, Vincent Descamps9, Fanny Domont10, Joëlle Faddoul10, Pierre-Edouard gavand11, Tiphaine Goulenok12, Baptiste Gramont13, Vincent Jachiet14, Gaëlle Leroux15, Matthieu Mahevas16, Julie Merindol17, Loïc Meudec18, Martin Michaud19, Morgane Mourguet20, Héloïse Munos pons21, Yann Nguyen22, Bénédicte Oules23, Thomas Papo24, Jacques Pouchot25, Sébastien Rivière14, Oscar Robert26, Charles ronsin27, Benjamin Rossi28, Delphine Staumont-salle29, Benjamin Terrier30, Nathalie Tieule31, Vollmer Olivier32, Pierre Wolkenstein33, Xavier Puéchal34, Jean-David Bouaziz35, Nicolas Dupin23, Gilles Peytavin36, Jean-Claude Alvarez37, Luc Mouthon38 and Alexis Régent34, 1Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France, Paris, France, 2Dermatology, Hôpital Tenon, Paris, France, 3Medical Intensive Care Unit and MP3CV-EA7517, Amiens University Hospital, Amiens, France, Amiens, France, 4Service de Médecine Interne et Immunologie Clinique, Hôpital de La Conception, Marseille, Marseille, France, 5Department of Internal Medicine, CHU Bordeaux, Bordeaux, France., Bordeaux, France, 6Service de Cardiologie, Hôpitaux Saint-Antoine and Tenon, AP-HP, 75012 Paris, France., Paris, France, 7Department of Dermatology and Reference Center for Rare Skin Diseases (MAGEC), Saint-Eloi Hospital, University of Montpellier and INSERM U1058, Montpellier, France., Montpellier, France, 8Clinique Universitaire de Médecine Interne, Department of Internal Medicine, Grenoble University Hospital, Grenoble, France, 9Department of Dermatology, APHP, Bichat Hospital, Paris, France., Paris, France, 10AP-HP. Centre de Référence des Maladies Auto-Immunes Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires et de l'Amylose Inflammatoire, F-75013 Paris, France., Paris, France, 11Department of Internal Medicine, Clinique Rhena, Strasbourg, France., Strasbourg, France, 12Assistance Publique Hôpitaux de Paris, Paris, France, 13Internal Medicine Departement, Saint Etienne, Saint Etienne, France, 14Service de médecine interne, AP-HP, Hôpital Saint Antoine, Sorbonne Universite, Paris, France., Paris, France, 15Service de Médecine Interne, AP-HP Hôpital Pitié-Salpêtrière, Paris, France., Paris, France, 16Department of Internal Medicine, APHP, Mondor Hospital, Paris, France., Créteil, France, 17Internal Medicine Department, University Hospital of Nice, Côte d'Azur University, Nice, Provence-Alpes-Côte d'Azur, France., Nice, France, 18Department of Rheumatology, Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France., Kremlin Bicêtre, France, 19Department of Internal Medicine, Clinique Saint-Exupery, Toulouse, France., Toulouse, France, 20service de médecine interne CHU Toulouse RANGUEIL, Toulouse, France, 21Department of Internal Medicine, Saint-Etienne University Hospital, Saint-Etienne, France., Saint Etienne, France, 22Université Paris Saclay, Clichy, Ile-de-France, France, 23Dermatology Department, Cochin Hospital, Paris, France., Paris, France, 24Université Paris Cité, Paris, France, 25Service de médecine Interne, Centre National de Référence des syndromes drépanocytaires majeurs de l'adulte, AP-HP, Hôpital Européen Georges Pompidou, Paris, France, Paris, France, 26Groupe Hospitalier Pitié Salpêtrière, Assistance Publique Hopitaux de Paris, Service de Pneumologie et Réanimation Médicale, Paris, France; [email protected]., Paris, France, 27cHD Vendée, La Roche sur Yon, La Roche sur Yon, France, 28Service de médecine interne, maladies infectieuses, Centre hospitalier intercommunal de Robert Ballenger, Aulnay-sous-bois, France., Aulnay-sous-bois, France, 29Service de dermatologie, CHU de Lille, université de Lille, 59000 Lille, France., Lille, France, 30Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, 31Rhumatologie, Centre Hospitalier Universitaire Nice, Hôpital Pasteur, Nice, France, 32Department of Immunology and Internal Medicine, Strasbourg University Hospital, Strasbourg, France., Strasbourg, France, 33Department of Dermatology, National Referral Center for Neurofibromatosis, Henri Mondor University Hospital, Assistance Publique- Hôpitaux de Paris, Creteil, France., Créteil, France, 34National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, 35Dermatology, Hopital Saint-Louis, Paris, Île-de-France, France., Paris, France, 36Service de Pharmacologie, Université Paris Cité, INSERM, IAME, UMR 1137, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France., Paris, France, 37Service de Pharmacologie‑Toxicologie, Hôpital Raymond Poincaré, Groupe Hospitalier Universitaires AP-HP.Paris-Saclay, Garches, 92380, France, Paris, France, 38Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

    Background/Purpose: Levamisole, an imidazothiazole formerly used as an anthelmintic, is also used as a cutting agent to enhance the effects and duration of cocaine. In…
  • « Previous Page
  • 1
  • …
  • 198
  • 199
  • 200
  • 201
  • 202
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology